Calamos Advisors LLC Makes New $523,000 Investment in AxoGen, Inc. (NASDAQ:AXGN)

Calamos Advisors LLC bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 31,725 shares of the medical equipment provider's stock, valued at approximately $523,000. Calamos Advisors LLC owned about 0.07% of AxoGen as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in AxoGen by 2,912.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider's stock worth $7,697,000 after buying an additional 530,775 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in AxoGen in the third quarter valued at about $5,789,000. FMR LLC increased its position in AxoGen by 743.1% in the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider's stock worth $2,509,000 after purchasing an additional 157,730 shares during the period. Eagle Asset Management Inc. acquired a new stake in AxoGen in the third quarter worth about $1,728,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in AxoGen by 66.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider's stock worth $4,328,000 after purchasing an additional 123,118 shares during the last quarter. 80.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. StockNews.com upgraded shares of AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. Canaccord Genuity Group lifted their target price on shares of AxoGen from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, February 3rd.

AxoGen Trading Down 2.0 %

AxoGen stock traded down $0.37 during midday trading on Friday, hitting $17.96. 301,986 shares of the stock were exchanged, compared to its average volume of 489,302. AxoGen, Inc. has a 52 week low of $5.55 and a 52 week high of $19.18. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $790.42 million, a PE ratio of -56.13 and a beta of 1.00. The company has a fifty day simple moving average of $16.60 and a two-hundred day simple moving average of $14.11.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.